National Ag News

Indianapolis-based Eli Lilly announced Tuesday it is exploring the possibility of spinning off or selling its animal health business, Elanco.   According to the Wall Street Journal, Lilly CEO Dave Ricks says the company is reviewing its options for Elanco now because acquisitions (the 2015 purchase of Novartis AG) have been mostly integrated, which helped to boost sales globally.  And he says in recent years the company relied on its animal business as a steady revenue source when patent expirations were hurting the human pharmaceutical business, which has since steadied.

Continue reading Eli Lilly explores sell-off of Elanco at Brownfield Ag News.